4q2525染色体における心房細動に対する独立した感受性マーカー
Steven A Lubitz1, Moritz F Sinner, Kathryn L Lunetta
1Cardiovascular Research Center, Massachusetts General Hospital, Charlestown, MA 02114, USA.
Circulation
|August 25, 2010
まとめ
染色体4q25の遺伝的変異は,心房細動 (AF) と関連しています. この研究では,この位置で2つの新しいAF感受性信号が発見され,リスク予測を改善しました.
科学分野:
- 遺伝学 遺伝学とは
- 心血管疾患 心血管疾患
背景:
- 染色体4q25の遺伝的変異は,心房細動 (AF) のリスク要因として知られています.
- 以前の研究では,この場所での複数の感受性信号の可能性を示唆していました.
研究 の 目的:
- 4q25 atrial fibrillationのロカスで1つ以上の感受性信号が存在するかどうかを調査する.
- AFリスクに関連した新しい遺伝マーカーを特定する.
主な方法:
- 発見コホートで4q25で34の単核性多形態体 (SNPs) をゲノタイプした.
- メタアナリシスを含む,大規模な独立したコホートで発見を複製した.
- 異なるAF信号をタグ付けするSNPを使用して,マルチマーカーリスクスコアを構築しました.
主要な成果:
- 既知のSNP rs2200733はAFと強い関連性を示した.
- rs2200733.3を調整した後に,rs17570669とrs3853445でマークされた2つの新しいAF感受性シグナルが識別されました.
- これらの3つの信号におけるリスクアレルの数が増加することは,AFのより高いリスクと相関していた.
結論:
- 染色体4q25.5の2つの新しい動感受性信号を特定しました.
- 4q25の複数の信号は,AFリスクの高い個人を特定することを強化します.
- これらの信号は,AFの病原性にとって極めて重要な規制要素を特定する可能性がある.
さらに関連する動画
関連する概念動画
Single Nucleotide Polymorphisms-SNPs
14.6K
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
14.6K
Genome-wide Association Studies-GWAS
12.6K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
12.6K
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
159
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
159
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
81
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
1.2K
Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...
1.2K


